NIH is moving the launch of its new website to the fall to ensure the best possible experience for everyone who relies on our websites for health information, research, funding opportunities, and other resources. Get the Latest Updates and FAQs
Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Scientists at the National Eye Institute and their colleagues have identified a gene responsible for some inherited retinal diseases (IRDs), which are a group of disorders that damage the eye’s light-sensing retina and threatens vision.
Trachomatous trichiasis can successfully be treated by either of the two most common types of eyelid surgery, according to findings from a large comparison trial funded by the National Institutes of Health.
A study supported by the National Institutes of Health (NIH) shows that 6.5 million Medicaid enrollees (12%) lived in states without coverage for routine adult eye exams; and 14.6 million (27%) resided in states without coverage for eyeglasses.
A study led by Georgetown University neuroscientists reveals that the part of the brain that receives and processes visual information in sighted people develops a unique connectivity pattern in people born blind.
Researchers have discovered a connection between levels of specific proteins in patients’ tears and persistent pain months after surgery such as LASIK.
Researchers have found that taking a daily supplement containing antioxidant vitamins and minerals slows progression of late-stage dry age-related macular degeneration (AMD), potentially helping people preserve their central vision.
Scientists from around the world gathered recently in Seattle, Washington, at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to address the global increase in myopia (nearsightedness).
Researchers at the University of Oklahoma Health Sciences and Memorial Sloan Kettering (MSK) Cancer Center are studying a new, revolutionary treatment for diabetic retinopathy that could change the prognosis for these patients.